The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ongoing Advocacy Efforts Seek Use of Complex Administration Codes for Biologics

Ongoing Advocacy Efforts Seek Use of Complex Administration Codes for Biologics

August 8, 2022 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The ACR and other advocacy organizations continue to work with the Centers for Medicare & Medicaid Services (CMS) to advocate for appropriate reimbursement of the administration of complex biologic therapies.

You Might Also Like
  • Defining Administration Complexity by the Drug, Not the Diagnosis
  • September Updates from the ACR Insurance Subcommittee
  • ACR Fights Cigna Decision to Eliminate Consultation Codes
Explore This Issue
November 2022
Also By This Author
  • Rheumatology Research Foundation Ranked in Top 2% of Charities by Charity Navigator

Over the past several years,  Medicare Administrative Contractors (MACs) have implemented Local Coverage Articles (LCAs) prohibiting the use of the chemotherapy administration codes (CPT 96401–96549) when coding for the administration of certain complex biologic drugs, instead requiring use of the diagnostic or therapeutic codes (CPT 96360–96379). The ACR has spoken with leaders from each of the MACs; however, they are unyielding in their opinion that this policy is accurate and appropriate.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In June, the ACR led a multispecialty sign-on letter asking the CMS to review the policymaking process used to implement these policy changes. The ACR was joined by nine other specialty societies in arguing that the MACs are using LCAs to bypass the more rigorous Local Coverage Determination process and subvert the transparency and stakeholder engagement intended by the 21st Century Cures Act. The letter asks the CMS to invalidate all current LCAs that restrict coverage or patient access.

In its response, the CMS acknowledged the concerns raised and suggested this specific issue may fall under the purview of its Center for Program Integrity (CPI). The ACR has subsequently reached out to the CPI and will pursue additional opportunities for dialogue.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For questions or additional information, contact [email protected]

Filed Under: Biologics & Biosimilars, Legislation & Advocacy Tagged With: ACR advocacy, biologic therapies, Local Coverage Article (LCA), Medicare Administrative Contractors (MACs)Issue: November 2022

You Might Also Like:
  • Defining Administration Complexity by the Drug, Not the Diagnosis
  • September Updates from the ACR Insurance Subcommittee
  • ACR Fights Cigna Decision to Eliminate Consultation Codes
  • Cigna to Eliminate Consultation Codes

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)